ClinicalTrials.gg
RecruitingNCT07554677PReFACeUpdated Oct 30, 2026

Understanding the Feasibility of a Co-designed Pre-radiotherapy Exercise Programme - A Single-arm Study

An interventional study of Exercise and radiotherapy in Lung Cancer, sponsored by Queen's University, Belfast. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Queen's University, Belfast · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 276 studies in Lung Neoplasms with a site in United Kingdom — 58 open to participants now, 83 under way, 24 of them phase 3. Lung Neoplasms · United Kingdom.

Planned enrollment
167th of 197
30 · median 200
Started
2026
with 8 others
No phase
46 of 276
9 open now
Primary completion
2027-01
later than 33 of 82 live
Registered
274th of 276
by date

Among the 276 studies in Lung Neoplasms with a site in United Kingdom, this one is the 167th largest by planned enrollment of the 197 interventional ones that give a count, is one of 9 that started in 2026, is one of 46 with no phase, reaches primary completion later than 33 of the 82 other live ones, and was the 274th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

58 of the 276 studies in Lung Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

52 more — sign in →

All 58 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Lung Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this clinical trial is to understand the feasibility of a co-designed, pre-radiotherapy exercise programme for people with stage I-III non-small cell lung cancer. This involves people with lung cancer engaging in 20 minutes exercises sessions performed within the radiotherapy department and immediately before each treatment at a personalised intensity.

The main questions it aims to answer are:

To understand the acceptability of the exercise programme through monitoring recruitment rates, attendance of the exercise sessions, and adherence to prescribed exercise intensities. Adverse events will also be monitored to understand programme safety.

Follow-up qualitative interviews will be conducted with participants, their family members, and health care professionals (HCP) to further explore the acceptability of the exercise programme.

In total, participants will be invited to perform up to twenty, supervised exercise sessions scheduled immediately before each treatment within the radiotherapy department. Each exercise session will be twenty minutes in duration and will be performed on a stationary exercise bike. Regarding exercise intensity, there are four levels which may be prescribed depending on people's exercise history, baseline exercise experience, and personal preference. Participants may progress or regress exercise intensity levels throughout the programme depending on their adherence and preference.

Read the detailed description

This is a sequential, mixed method feasibility study consisting of two phases:

Phase 1: Quantitative data collection (feasibility outcomes)

Phase 2: Qualitative data collection (semi-structured interviews)

The exercise programme used in this study was co-designed through a series of workshops and meetings involving individuals affected by lung cancer and healthcare professionals.

Eligible participants must be receiving a prescribed radiotherapy dose of either 55 Gy delivered in twenty fractions or 66Gy administered in 15 fractions, adminstered daily over a 3-4 week period. Accordingly, participants will be prescribed either 15 or 20 exercise sessions, performed once daily and scheduled in alignment with their radiotherapy treatment.

Exercise intensity is personalised and based on a submaximal exercise test conducted at the participant's baseline assessment. This test will be used to determine each participant's maximum heart rate, which will then be entered into the Karvonen formula (Karvonen et al., 1957) to calculate percentage heart rate reserve. This calculation will establish individual heart-rate ranges corresponding to light, moderate, and vigorous exercise intensities. Starting exercise intensity level (1-4) will be determined based on a baseline six-minute walking test, clinical frailty score, and participant preference.

The four levels of exercise intensity increase in difficulty, and incorporate various durations of light, moderate, or high intensity exercise, including:

  • Level 1: 10-minute warm-up at light intensity continuous cycling followed by 10 minutes of moderate intensity continuous cycling
  • Level 2: 5-minute warm-up at light intensity continuous cycling followed by 15 minutes of moderate intensity continuous cycling
  • Level 3: 5-minute warm-up at light intensity continuous cycling, followed by 10 minutes of moderate intensity continuous cycling, and 5 minutes of 30-second-high intensity intervals
  • Level 4: 5-minute warm-up at light intensity continuous cycling, followed by 5 minutes of 30-second-high intensity intervals, 5 minutes of moderate intensity continuous cycling, and 5 minutes of 30-second-high intensity intervals

All participants will wear a chest-strap heart-rate monitor during each exercise session to ensure they are exercising at the prescribed intensity. Session adherence will be defined as completion of at least 75% of the prescribed exercise duration (i.e. 15-minutes).

03

Conditions studied

  • Lung Cancer

Keywords

  • Radiotherapy
  • Clinical Trial
  • Exercise
  • Physical Activity
  • feasibility
  • co-design
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with clinically or confirmed NSCLC stages 1-3.
  • Planned to receive treatment with curative intention radiation as primary treatment.
  • (ECOG) performance status 0-2.
  • At least 18 years of age.
  • Can understand and communicate in English.
  • Deemed safe to participate in moderate-intensity exercise and for monitored maximal fitness test through the completion of a medical clearance form by their treating physician.
  • Able to provide written and .

Exclusion criteria

Exclusion Criteria:

  • Unstable or new angina (diagnosed within the previous month).
  • Unstable or acute heart failure, cardiomyopathy, or other uncontrolled cardiac disease (as evidenced by symptomatic fluid retention, excessive breathlessness, rapid weight gain, swollen ankles or pitting oedema) within the previous 3 months.
  • Presence of new or uncontrolled cardiac arrhythmias.
  • Confirmed or suspected spinal cord compression.
  • Uncontrolled diabetes (e.g. medication changed within 1 month, has had episodes of hypoglycaemia during the previous 2 weeks, or hyperglycaemia which does not decrease with exercise during the previous 2 weeks).
  • Is receiving combination treatment with chemotherapy or immunotherapy.
  • Current active secondary other than non-melanoma skin cancer.
  • Has had orthopaedic surgery within the previous 3 months on weight-bearing bones.
  • Chest pain while undertaking exercise or physical activity.
  • No > Grade 2 peripheral neuropathy.
  • disease beyond localised metastatic involvement (e.g. bone or brain).
  • Has discovered any abnormalities shown on the monitored maximal fitness test which warrant early termination or contraindicate physical activity.
  • People with living with a physical disability which would limit their ability to exercise safely on the stationary exercise bike used within this study.
  • People who are non-English speakers.
  • People who are pregnant.

    • Patient participation in other clinical research - As an additional consideration, patients will be excluded if they are currently enrolled in an alternative exercise or physical activity study, as this may impact outcomes in both studies. However, if they have been involved in research prior to this or are currently involved in research in an unrelated area we will not immediately exclude them from trial participation. Instead, the Doctor of Philosophy (PhD) candidate, Chief investigator, and Principal investigator will discuss their involvement to determine safe and appropriate enrolment.
    • Physical disability - it is with regret that we will be limited in our capacity to offer alternative exercises to accommodate people with a physical disability. To elaborate, the Belfast City Hospitals (BCH) main gym is willing to lend a stationary exercise bike to the research team in support of this study. However, due to limitations on equipment availability in the trust, and limited funding/resources to purchase equipment, people who have a physical disability which limits their capacity to exercise safely on the stationary bike will be excluded from this study. In an ideal scenario, we would also have a recumbent stationary bike to support more people with physical disability get involved within this research.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Pre-Radiotherapy exercise arm

    Participants within the experimental arm will participate in the co-designed, pre-radiotherapy exercise programme alongside treatment.

    Other: Exercise · Radiation: radiotherapy

Interventions

  • OtherExercise

    Participants will participate in up to twenty, supervised exercise sessions, performed within the radiotherapy department, immediately before each treatment. Each session has a 20 minute duration at one of four exercise intensity levels based on the participants baseline assessment results, and preferences.

  • Radiationradiotherapy

    Study participants will have been diagnosed with stage I-III NSCLC and prescribed radiotherapy administered as 55Gy in 20 fractions over 4 weeks or 60Gy in 15 fractions over 3 weeks as their primary treatment as per standard treatment pathways within the trust

06

What researchers measure

Primary outcomes

  1. Eligibility rates

    The percentage of eligible participants identified and approached through participant screening

    Time frame: Screening and enrolment

  2. Recruitment rate

    The total number of potential participants who were approached and agreed to participate as a percentage of the total number who were approached

    Time frame: Screening and recruitment

  3. Exercise programme attendance

    The total number of attended sessions by the total number provided

    Time frame: Weeks 4-8 (PReFACe exercise programme)

  4. Adherence to the exercise programme

    Monitoring the participants ability to complete the advised duration and intensity of exercise during each session (adherence is accepted if completed 75% of duration without intensity modification)

    Time frame: Weeks 4-8 (PReFACe exercise programme)

  5. Participant retention rates

    The number of participants available to provide outcomes at the post-intervention assessment as a percentage of the total number recruited.

    Time frame: Week 0 (baseline assessment) to week 8 (PReFACe exercise programme end and post-intervention assessment)

  6. Adverse event Common Terminology Criteria for Adverse Events (CTCAE) v5

    Assess the tolerability and safety of the intervention, via recording of intervention-associated adverse events (AE). AEs will be graded according to CTCAE v.5 as: * Grade 1 = Mild * Grade 2 = Moderate * Grade 3 = Severe * Grade 4 = Life-threatening consequences * Grade 5 = Death related to AE

    Time frame: Week 0 (baseline assessment) to week 8 (PReFACe exercise programme end and post-intervention assessment)

Secondary outcomes

  1. Change from baseline in quality of life using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-items (EORTC QLQ-30)

    EORTC QLQ-30 is a reliable and validated, multidimensional quality-of-life questionnaire which is widely used in research for people with lung cancer. The QLQ-C30 is composed of both multi-item scales and single-item measures, including: Five functional scales: * Physical * Role * Emotional * Cognitive * Social Three symptoms' scales: * Fatigue * Nausea and Vomiting * Pain A Global health Status (QoL) Six single items: * Dyspnoea * Insomnia * Appetite loss * Constipation * Diarrhoea * Financial difficulties All scales and single-item measures range in score from 0 to 100. High scale scores represent a higher response level, thus: * High scores for functional sales = high/healthy levels of functioning * High global health status = high QoL * High symptom scale/ single item scores = higher symptom burden

    Time frame: Week 0 (baseline assessment) to week 8 (end of study assessment)

  2. Change from baseline in quality of life using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-LC13)

    EORTC QLQ-LC13 is a reliable and validated, multidimensional quality-of-life questionnaire which is widely used in research for people with lung cancer. The QLQ-LC13 incorporates one multi-item scale to assess dyspnoea, and a series of single items assessing: * Pain * Coughing * Sore mouth * Dysphagia * Peripheral Neuropathy * Alopecia * Haemoptysis All single-item measures range in score from 0 to 100 with high scale scores representing a higher response level, thus: \- High symptom scale/ single item scores = higher symptom burden

    Time frame: Week 0 (baseline assessment) to week 8 (end of study assessment)

  3. Impact of exercise programmes effect on symptom burden: Pain likert Scale

    Understanding the impact of the exercise programme on symptom burden on participants experience of pain using a 1-10 likert scale: * Scores 1-3 = Mild Pain * Scores 4-7 = Moderate pain * Scores 8-10 = Severe pain

    Time frame: Week 0 (baseline assessment) to week 8 (end of study assessment)

  4. Impact of exercise programmes effect on symptom burden: Fatigue likert Scale

    Understanding the impact of the exercise programme on symptom burden on participants experience of fatigue using a 1-10 likert scale: * Scores 1-2 = No fatigue * Scores 3-4 = Minor fatigue * Scores 5-6 = Moderate fatigue * Scores 7-8 = Significant fatigue * Scores 9-10 = Extreme fatigue

    Time frame: Week 0 (baseline assessment) to week 8 (end of study assessment)

  5. Impact of exercise programmes effect on symptom burden: Modified Medical Research Council (MRC) dyspnoea scale

    The modified MRC dyspnoea scale is a 5-point (0-4) questionnaire that assesses a patient's breathing difficulty, or dyspnoea, during activity. Higher scores correspond with more breathlessness etc: * grade 0 = breathless with strenuous exercise * grade 1 = short of breath when hurrying on level ground or walking up a slight hill * grade 2 = on level ground, I walk slower than people of my age because of breathlessness * grade 3 = I stop for breath after walking about 100 yards or after a few minutes on level ground * grade 4 = Too breathless to leave the house or I am breathless when dressing/undressing

    Time frame: Week 0 (baseline assessment), daily through PReFACe exercise programme (weeks 4-8) and end of study assessment (week 8)

  6. To assess the accessibility, acceptability and experience of the exercise programme through semi-structured qualitative interviews

    Conduct of post-intervention, semi-structured, qualitative interviews with the following groups: 1. Phase 1 participants (who have completed the programme or withdrew from the programme) 2. Phase 1 participants nominated person (friend or family) 3. Healt Care Professionals (HCPs) involved/ exposed to the study A total of 15 participants (n=5 from each group) is deemed sufficient to achieve data saturation. Semi-structured interview schedules were pre-constructed for each group. Interview schedules consist of open-ended questions to explore the participants/experience of the exercise programme in their own words. No scales are used as a part of this outcome.

    Time frame: Weeks 8-14 post-intervention follow-up period

  7. Baseline compared to post-intervention changes in participant distress levels using the National Comprehensive Cancer Network (NCCN) Distress thermometer.

    The distress thermometer is a valid, and accurate screening tool used to quickly monitor for patient's distress with advanced cancer. The thermometer uses a 0-10 scale to measure patient distress over the past week with 0 representing no distress and 10 representing extreme distress. The thermometer also features a "Problem List" (covering practical, family, emotional, spiritual, and physical issues) to pinpoint causes of distress for referral

    Time frame: Baseline assessment (week 0), weekly throughout the PReFACe exercise programme (weeks 4-8) and at post-study assessment (week 8)

  8. Change in baseline to post-intervention physical fitness: Six- minute walking test

    A well-documented, validated and standardised sub-maximal fitness test measuring the distance a person can walk on a flat, solid surface in six minutes. Participants walk back and forth along a measured track to measure total distance covered in meters within six minutes. Greater distance covered (meters) indicate greater baseline fitness. Greater post-test distance covered (meters) than baseline scores indicate improvements in basic mobility. Reduced post-test distance covered (meters) than baseline scores indicate reductions in basic mobility.

    Time frame: Baseline assessment (week 0) and post-study assessment (week 8)

  9. Change in baseline to post-intervention physical fitness: 30-second sit-to-stand

    A well-documented, validated, and standardised test to measure functional lower extremity strength. Participants perform as many sit-to-stand reps as they can within 30 seconds.

    Time frame: Baseline assessment (week 0) and post-study assessment (week 8)

  10. Change in baseline to post-intervention physical functioning: Rockwood Clinical Frailty Scale (CFS)

    The Rockwood CFS is used as a valid assessment tool for screening frailty in older adults. This is a 1-9 scale, with higher scores indicating greater frailty: 1. Very fit 2. Well 3. Managing well 4. Vulnerable 5. Mildly frail 6. Moderately frail 7. Severely frail 8. Very severely frail 9- Terminally ill

    Time frame: Baseline assessment (week 0) and post-study assessment (week 8)

  11. Change in baseline to post-intervention physical activity: The International Physical Activity Questionnaire - Short Form (IPAQ-SF)

    The IPAQ-SF will be used to explore the influence of the pre-radiotherapy exercise programme on the participant's weekly physical activity levels pre- and post-study. Based on results, physical activity levels based on scores can be calculated as: 1. Inactive 2. Minimally active 3. HEPA active (health enhancing physical activity; a high active category)

    Time frame: Baseline assessment (week 0) and post-study assessment (week 8)

  12. Change in baseline to post-intervention physical activity: Huffman Exercise Satisfactions Scale

    The Huffman Exercise Satisfaction Scale was developed with stakeholders as a novel approach to measure older adults (aged ≥55 years) satisfaction with their physical activity levels. There questionnaire measures two scales: 1. A Physical activity enjoyment scale, consisting of 8 multiple choice questions. Responses are allocated a range from 1 to 7 with higher values indicate higher levels of enjoyment of physical activity 2. Satisfaction measure, consists of 4, multiple choice questions. Responses to the satisfaction items range from 1 to 7, with higher values indicating higher levels of satisfaction with physical activity. Mean scores are taken from each scale to total participants exercise enjoyment and satisfaction.

    Time frame: Baseline assessment (week 0) and post-study assessment (week 8)

07

Study locations

1 of 1 sites recruiting
  • Northern Ireland Cancer Centre, City Hospital, BHSCT
    Belfast, Antrim BT9 7JL, United Kingdom
    Recruiting
    • Matthew Peter Beggs, MSc, BSc · Contactmbeggs06@qub.ac.uk · +44 7759264875
    • Cathryn Dr Crockett, Consultant Clinical Oncologist · Principal investigator
08

References and documents

Publications

  • Ziolkowska-Suchanek I. Mimicking Tumor Hypoxia in Non-Small Cell Lung Cancer Employing Three-Dimensional In Vitro Models. Cells. 2021 Jan 12;10(1):141. doi: 10.3390/cells10010141. PubMed 33445709 ↗
  • Seet-Lee C, Yee J, Morahan H, Ross LS, Edwards KM. The effect of aerobic exercise on tumour blood delivery: a systematic review and meta-analysis. Support Care Cancer. 2022 Nov;30(11):8637-8653. doi: 10.1007/s00520-022-07132-0. Epub 2022 Jun 2. PubMed 35650456 ↗
  • Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for prescription in exercise-oncology research. J Cachexia Sarcopenia Muscle. 2015 Jun;6(2):115-24. doi: 10.1002/jcsm.12042. Epub 2015 May 11. PubMed 26136187 ↗
  • World Health Organization (2023) Lung Cancer
  • World Health Organization (2018) More active people for a healthier world
  • Williams, N. (2017) 'The Borg Rating of Perceived Exertion (RPE) scale ', Occupational Medicine, 67 (5), pp. 404-405.
  • Vinod SK, Hau E. Radiotherapy treatment for lung cancer: Current status and future directions. Respirology. 2020 Nov;25 Suppl 2:61-71. doi: 10.1111/resp.13870. Epub 2020 Jun 9. PubMed 32516852 ↗
  • Viamonte SG, Joaquim AV, Alves AJ, Vilela E, Capela A, Ferreira C, Duarte BF, Rato ND, Teixeira MP, Tavares A, Santos M, Ribeiro F. Cardio-Oncology Rehabilitation for Cancer Survivors With High Cardiovascular Risk: A Randomized Clinical Trial. JAMA Cardiol. 2023 Dec 1;8(12):1119-1128. doi: 10.1001/jamacardio.2023.3558. PubMed 37819656 ↗
  • United Kingdom Lung Cancer Coalition (2024) Driving Quality Improvements in UK Lung Cancer: Utilising good practice and innovation to deliver optimal care and outcomes
  • Varkey B. Principles of Clinical Ethics and Their Application to Practice. Med Princ Pract. 2021;30(1):17-28. doi: 10.1159/000509119. Epub 2020 Jun 4. PubMed 32498071 ↗
  • Tran DL, Kamaladasa Y, Munoz PA, Kotchetkova I, D'Souza M, Celermajer DS, Maiorana A, Cordina R. Estimating exercise intensity using heart rate in adolescents and adults with congenital heart disease: Are established methods valid? Int J Cardiol Congenit Heart Dis. 2022 Mar 26;8:100362. doi: 10.1016/j.ijcchd.2022.100362. eCollection 2022 Jun. PubMed 39712058 ↗
  • Totton N, Lin J, Julious S, Chowdhury M, Brand A. A review of sample sizes for UK pilot and feasibility studies on the ISRCTN registry from 2013 to 2020. Pilot Feasibility Stud. 2023 Nov 21;9(1):188. doi: 10.1186/s40814-023-01416-w. PubMed 37990337 ↗
  • Toohey K, Mizrahi D, Hart NH, Singh B, Lopez P, Hunter M, Newton RU, Schmitz KH, Adams D, Edbrooke L, Hayes S. Exercise in cancer care for people with lung cancer: A narrative synthesis. J Sci Med Sport. 2025 Jan;28(1):16-25. doi: 10.1016/j.jsams.2024.08.002. Epub 2024 Aug 8. PubMed 39155211 ↗
  • Tivey A, Ullah M, Beech A, Ng C, Cove-Smith L. Can frailty screening tools predict completion of chemotherapy and chemotherapy toxicity in patients with thoracic malignancy? J Geriatr Oncol. 2020 Sep;11(7):1154-1156. doi: 10.1016/j.jgo.2020.03.002. Epub 2020 Mar 11. No abstract available. PubMed 32171694 ↗
  • Suveg K, Plasswilm L, Iseli T, Leskow P, Fischer GF, Putora PM. Role of Adjuvant Radiotherapy in Non-Small Cell Lung Cancer-A Review. Cancers (Basel). 2022 Mar 23;14(7):1617. doi: 10.3390/cancers14071617. PubMed 35406388 ↗
  • Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, Boyd KA, Craig N, French DP, McIntosh E, Petticrew M, Rycroft-Malone J, White M, Moore L. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ. 2021 Sep 30;374:n2061. doi: 10.1136/bmj.n2061. PubMed 34593508 ↗
  • Sia J, Szmyd R, Hau E, Gee HE. Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer. Front Cell Dev Biol. 2020 Feb 13;8:41. doi: 10.3389/fcell.2020.00041. eCollection 2020. PubMed 32117972 ↗
  • Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005 Aug 30;173(5):489-95. doi: 10.1503/cmaj.050051. PubMed 16129869 ↗
  • Riba MB, Donovan KA, Ahmed K, Andersen B, Braun I, Breitbart WS, Brewer BW, Corbett C, Fann J, Fleishman S, Garcia S, Greenberg DB, Handzo GF, Hoofring LH, Huang CH, Hutchinson S, Johns S, Keller J, Kumar P, Lahijani S, Martin S, Niazi SK, Pailler M, Parnes F, Rao V, Salman J, Scher E, Schuster J, Teply M, Usher A, Valentine AD, Vanderlan J, Lyons MS, McMillian NR, Darlow SD. NCCN Guidelines(R) Insights: Distress Management, Version 2.2023. J Natl Compr Canc Netw. 2023 May;21(5):450-457. doi: 10.6004/jnccn.2023.0026. PubMed 37156476 ↗
  • Piraux E, Caty G, Aboubakar Nana F, Reychler G. Effects of exercise therapy in cancer patients undergoing radiotherapy treatment: a narrative review. SAGE Open Med. 2020 Jun 17;8:2050312120922657. doi: 10.1177/2050312120922657. eCollection 2020. PubMed 32595968 ↗
  • Pinto BM, Ciccolo JT. Physical activity motivation and cancer survivorship. Recent Results Cancer Res. 2011;186:367-87. doi: 10.1007/978-3-642-04231-7_16. PubMed 21113773 ↗
  • Penko AL, Barkley JE, Koop MM, Alberts JL. Borg scale is valid for ratings of perceived exertion for individuals with Parkinson's disease. Int J Exerc Sci. 2017 Jan 1;10(1):76-86. doi: 10.70252/RVAQ3828. eCollection 2017. PubMed 28479949 ↗
  • Peddle-McIntyre CJ, Singh F, Thomas R, Newton RU, Galvao DA, Cavalheri V. Exercise training for advanced lung cancer. Cochrane Database Syst Rev. 2019 Feb 11;2(2):CD012685. doi: 10.1002/14651858.CD012685.pub2. PubMed 30741408 ↗
  • Pearson N, Naylor PJ, Ashe MC, Fernandez M, Yoong SL, Wolfenden L. Guidance for conducting feasibility and pilot studies for implementation trials. Pilot Feasibility Stud. 2020 Oct 31;6(1):167. doi: 10.1186/s40814-020-00634-w. PubMed 33292770 ↗
  • Ortmann BM. Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity. BMJ Oncol. 2024 Feb 1;3(1):e000154. doi: 10.1136/bmjonc-2023-000154. eCollection 2024. PubMed 39886164 ↗
  • Norton K, Norton L, Sadgrove D. Position statement on physical activity and exercise intensity terminology. J Sci Med Sport. 2010 Sep;13(5):496-502. doi: 10.1016/j.jsams.2009.09.008. Epub 2009 Dec 10. PubMed 20005170 ↗
  • Nisar H, Sanchidrian Gonzalez PM, Brauny M, Labonte FM, Schmitz C, Roggan MD, Konda B, Hellweg CE. Hypoxia Changes Energy Metabolism and Growth Rate in Non-Small Cell Lung Cancer Cells. Cancers (Basel). 2023 Apr 26;15(9):2472. doi: 10.3390/cancers15092472. PubMed 37173939 ↗
  • Nikitara K, Odani S, Demenagas N, Rachiotis G, Symvoulakis E, Vardavas C. Prevalence and correlates of physical inactivity in adults across 28 European countries. Eur J Public Health. 2021 Oct 11;31(4):840-845. doi: 10.1093/eurpub/ckab067. PubMed 34000007 ↗
  • National Institute of Health, (2021). Common Terminology Criteria for Adverse Events (CTCAE)
  • National Institute for Health and Care Excellence (2014) Behaviour Change: Individual Approaches
  • National Data Guardian (2020) The Eight Caldicott Principles.
  • Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015 Dec 11;3:83-92. doi: 10.2147/HP.S93413. eCollection 2015. PubMed 27774485 ↗
  • Morgan B, Hejdenberg J, Kuleszewicz K, Armstrong D, Ziebland S. Are some feasibility studies more feasible than others? A review of the outcomes of feasibility studies on the ISRCTN registry. Pilot Feasibility Stud. 2021 Nov 8;7(1):195. doi: 10.1186/s40814-021-00931-y. PubMed 34749831 ↗
  • Moreton, R., Stutz, A., Robinson, S., Mulla, I., Winter, M., Roberts, J. & Hillsdon, M. (2018) Evaluation of the Macmillan Physical Activity Behaviour Change Care Pathway
  • Moreno-Arino M, Torrente Jimenez I, Cartanya Gutierrez A, Oliva Morera JC, Comet R. Assessing the strengths and weaknesses of the Clinical Frailty Scale through correlation with a frailty index. Aging Clin Exp Res. 2020 Nov;32(11):2225-2232. doi: 10.1007/s40520-019-01450-w. Epub 2020 Jan 2. PubMed 31898172 ↗
  • Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011 Apr 23;6:42. doi: 10.1186/1748-5908-6-42. PubMed 21513547 ↗
  • McCullough DJ, Stabley JN, Siemann DW, Behnke BJ. Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. J Natl Cancer Inst. 2014 Apr;106(4):dju036. doi: 10.1093/jnci/dju036. Epub 2014 Mar 13. PubMed 24627275 ↗
  • Macmillan (2023) Physical Activity and Cancer
  • Lumivero (2017) NVivo (Version 12).
  • Ligibel JA, Bohlke K, Alfano CM. Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline Summary and Q&A. JCO Oncol Pract. 2022 Oct;18(10):695-697. doi: 10.1200/OP.22.00277. Epub 2022 Jul 5. No abstract available. PubMed 35787022 ↗
  • Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023 Apr 12;8(1):160. doi: 10.1038/s41392-023-01419-2. PubMed 37045827 ↗
  • Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act. 2011 Oct 21;8:115. doi: 10.1186/1479-5868-8-115. PubMed 22018588 ↗
  • Koller M, Musoro JZ, Tomaszewski K, Coens C, King MT, Sprangers MAG, Groenvold M, Cocks K, Velikova G, Flechtner HH, Bottomley A. Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma - Interpretation guidance derived from two randomized EORTC trials. Lung Cancer. 2022 May;167:65-72. doi: 10.1016/j.lungcan.2022.03.018. Epub 2022 Mar 29. PubMed 35413526 ↗
  • Kirkham AA, Campbell KL, McKenzie DC. Comparison of aerobic exercise intensity prescription methods in breast cancer. Med Sci Sports Exerc. 2013 Aug;45(8):1443-50. doi: 10.1249/MSS.0b013e3182895195. PubMed 23439424 ↗
  • Kilari D, Soto-Perez-de-Celis E, Mohile SG, Alibhai SM, Presley CJ, Wildes TM, Klepin HD, Demark-Wahnefried W, Jatoi A, Harrison R, Won E, Mustian KM. Designing exercise clinical trials for older adults with cancer: Recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting. J Geriatr Oncol. 2016 Jul;7(4):293-304. doi: 10.1016/j.jgo.2016.04.007. Epub 2016 May 31. PubMed 27197916 ↗
  • KARVONEN MJ, KENTALA E, MUSTALA O. The effects of training on heart rate; a longitudinal study. Ann Med Exp Biol Fenn. 1957;35(3):307-15. No abstract available. PubMed 13470504 ↗
  • Kallio H, Pietila AM, Johnson M, Kangasniemi M. Systematic methodological review: developing a framework for a qualitative semi-structured interview guide. J Adv Nurs. 2016 Dec;72(12):2954-2965. doi: 10.1111/jan.13031. Epub 2016 Jun 23. PubMed 27221824 ↗
  • Huffman MK, Christ SL, Ferraro KF, Klenosky DB, Marceau K, Amireault S. Questions to Measure Enjoyment of and Satisfaction With Physical Activity: Are They Appropriate for Use in an Older Population? Innov Aging. 2021 Oct 4;5(4):igab041. doi: 10.1093/geroni/igab041. eCollection 2021. PubMed 34988294 ↗
  • Hircock C, Wang AJ, Goonaratne E, Sferrazza D, Bottomley A, Cella D, Lee SF, Chan AW, Chow E, Wong HCY. Comparing the EORTC QLQ-LC13, EORTC QLQ-LC29, and the FACT-L for assessment of quality of life in patients with lung cancer - an updated systematic review. Curr Opin Support Palliat Care. 2024 Dec 1;18(4):260-268. doi: 10.1097/SPC.0000000000000725. Epub 2024 Oct 30. PubMed 39269263 ↗
  • Graham-Wisener L, Dempster M, Sadler A, McCann L, McCorry NK. Validation of the Distress Thermometer in patients with advanced cancer receiving specialist palliative care in a hospice setting. Palliat Med. 2021 Jan;35(1):120-129. doi: 10.1177/0269216320954339. Epub 2020 Sep 11. PubMed 32912055 ↗
  • Esteves M, Monteiro MP, Duarte JA. The Effects of Physical Exercise on Tumor Vasculature: Systematic Review and Meta-analysis. Int J Sports Med. 2021 Dec;42(14):1237-1249. doi: 10.1055/a-1533-1876. Epub 2021 Aug 2. PubMed 34341974 ↗
  • Egegaard T, Rohold J, Lillelund C, Persson G, Quist M. Pre-radiotherapy daily exercise training in non-small cell lung cancer: A feasibility study. Rep Pract Oncol Radiother. 2019 Jul-Aug;24(4):375-382. doi: 10.1016/j.rpor.2019.06.003. Epub 2019 Jun 21. PubMed 31289452 ↗
  • Dufresne S, Gueritat J, Chiavassa S, Noblet C, Assi M, Rioux-Leclercq N, Rannou-Bekono F, Lefeuvre-Orfila L, Paris F, Rebillard A. Exercise training improves radiotherapy efficiency in a murine model of prostate cancer. FASEB J. 2020 Apr;34(4):4984-4996. doi: 10.1096/fj.201901728R. Epub 2020 Feb 11. PubMed 32043634 ↗
  • Cormie P, Zopf EM, Zhang X, Schmitz KH. The Impact of Exercise on Cancer Mortality, Recurrence, and Treatment-Related Adverse Effects. Epidemiol Rev. 2017 Jan 1;39(1):71-92. doi: 10.1093/epirev/mxx007. PubMed 28453622 ↗
  • Coletta AM, Basen-Engquist KM, Schmitz KH. Exercise Across the Cancer Care Continuum: Why It Matters, How to Implement It, and Motivating Patients to Move. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-7. doi: 10.1200/EDBK_349635. PubMed 35394822 ↗
  • Cleland BT, Ingraham BA, Pitluck MC, Woo D, Ng AV. Reliability and Validity of Ratings of Perceived Exertion in Persons With Multiple Sclerosis. Arch Phys Med Rehabil. 2016 Jun;97(6):974-82. doi: 10.1016/j.apmr.2016.01.013. Epub 2016 Feb 1. PubMed 26836954 ↗
  • Church S, Rogers E, Rockwood K, Theou O. A scoping review of the Clinical Frailty Scale. BMC Geriatr. 2020 Oct 7;20(1):393. doi: 10.1186/s12877-020-01801-7. PubMed 33028215 ↗
  • Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995 Jun;12(3):199-220. doi: 10.1016/0169-5002(95)00450-f. PubMed 7655830 ↗
  • Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, Zucker DS, Matthews CE, Ligibel JA, Gerber LH, Morris GS, Patel AV, Hue TF, Perna FM, Schmitz KH. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390. doi: 10.1249/MSS.0000000000002116. PubMed 31626055 ↗
  • Brown M, Rebillard A, Hart NH, O'Connor D, Prue G, O'Sullivan JM, Jain S. Modulating Tumour Hypoxia in Prostate Cancer Through Exercise: The Impact of Redox Signalling on Radiosensitivity. Sports Med Open. 2022 Apr 8;8(1):48. doi: 10.1186/s40798-022-00436-9. PubMed 35394236 ↗
  • Bradley, P., Merchant, Z., Rowlinson-Groves, K., Grundy, S., Al-Najjar, H., Brown, L., Dand, A., Farran, C., Bayman, N., Banfill, K., Wray, D., Moore, J. & Evison, M. (2021) 'P212 Prehab4Cancer: an innovative regional lung cancer prehabilitation service', Thorax, 76 (1), pp. A204-A205
  • Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer. 1994;30A(5):635-42. doi: 10.1016/0959-8049(94)90535-5. PubMed 8080679 ↗
  • Beale, L., Carter, H., Doust, J., Brickley, G., Silberbauer, J. & Llyod, G. (2010) 'Exercise heart rate guidelines overestimate recommended intensity for chronic heart failure patients', British Journal of Cardiology, 17, pp.133-137.
  • Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015 Jul;15(7):409-25. doi: 10.1038/nrc3958. PubMed 26105538 ↗
  • Balachandran AT, Vigotsky AD, Quiles N, Mokkink LB, Belio MA, Glenn JM. Validity, reliability, and measurement error of a sit-to-stand power test in older adults: A pre-registered study. Exp Gerontol. 2021 Mar;145:111202. doi: 10.1016/j.exger.2020.111202. Epub 2020 Dec 19. PubMed 33347922 ↗
  • Avancini A, Sartori G, Gkountakos A, Casali M, Trestini I, Tregnago D, Bria E, Jones LW, Milella M, Lanza M, Pilotto S. Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled? Oncologist. 2020 Mar;25(3):e555-e569. doi: 10.1634/theoncologist.2019-0463. Epub 2019 Nov 26. PubMed 32162811 ↗
  • Atun R, Jaffray DA, Barton MB, Bray F, Baumann M, Vikram B, Hanna TP, Knaul FM, Lievens Y, Lui TY, Milosevic M, O'Sullivan B, Rodin DL, Rosenblatt E, Van Dyk J, Yap ML, Zubizarreta E, Gospodarowicz M. Expanding global access to radiotherapy. Lancet Oncol. 2015 Sep;16(10):1153-86. doi: 10.1016/S1470-2045(15)00222-3. PubMed 26419354 ↗
  • Association of Chartered Physiotherapists in Cardiovascular Rehabilitation (2023) Standards for Physical Activity and Exercise in the Cardiovascular Population: 4th Edition
  • Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365. PubMed 8433390 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Currently under review with supervisory team

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2027, 7 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 7 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Dec 2026 → Jan 2027 and completion Dec 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
Apr 28, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Jan 14, 2027was Dec 2026
CompletionEst.
Jan 14, 2027was Dec 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 1, 2026→Jan 14, 2027
Oct 30, 2026
Study completion
Dec 2026→Jan 14, 2027
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Primary completion Dec 1, 2026→Jan 14, 2027
    Study completion Dec 2026→Jan 14, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07554677
Responsible party
Gillian Prue (Dr Gillian Prue PhD., HCPC registered, FHEA, MCSP, Queen's University, Belfast) — Principal investigator
First posted
Apr 28, 2026
Start date
Jun 2, 2026
Primary completion
Jan 14, 2027 (estimated)
Completion
Jan 14, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Matthew Peter Beggs, MSc, BSc
Contact
mbeggs06@qub.ac.uk
+44 7759264875.
Gillian Dr Prue, PhD., HCPC, FHEA, MCSP
Contact
g.prue@qub.ac.uk
+44 28 9097 2345

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion